Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
By J. Cooper, T. Pajak, A. Forastiere, J. Jacobs, B. Campbell, S. Saxman, J. Kish, Harold Kim, A. Cmelak, M. Rotman and 6 more. New England Journal of Medicine, 2004
3,023 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Surgery
View Paper: https://www.semanticscholar.org/paper/69d814bb135c1d08a7d093e515333d77cbf123f2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
In Surgery
Citations in the corpus
- Oral cavity and oropharyngeal squamous cell carcinoma—an update (2015, background): “and the need for adjuvant radiation or chemoradiation therapy often dictated by adverse findings (eg, positive surgical margins, perineural or lymphovascular invasion, N2 or N3 lymph node disease, lymph node disease in levels IV or V, extracapsular extension of tumor in lymph nodes).(174-176) Althou”
- Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005, methodology): “First, a previous RTOG study (RTOG 8503), which tested the value of sequential postoperative chemotherapy and radiation therapy,(7) suggested three risk groupings: (1) lowest risk when fewer than two nodes were histologically involved, no ECE was present, and surgical margins were not histologically”
- Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond (2005, result): “While it logically follows that if concurrent chemotherapy confers a benefit to radiation in the definitive setting, it would add a similar benefit in the postoperative setting; this had not been shown until the publication of two landmark trials earlier this year.(57,58) Two similar trials, one in ”